Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a tafasitamab study in adults with primary ITP or warm autoimmune hemolytic anemia
2025-521286-27-00Phase 3Authorised
- Sponsor
- Incyte
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 3, open-label trial of tafasitamab in immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) (2 arms), sponsored by Incyte. Primary endpoints: Safety and tolerability, Stable platelet response and 1 more. Planned start Feb 2026; status: authorised.
02
Drugs
tafasitamab
03
Conditions
immune thrombocytopenia (ITP)warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on 2025-521286-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521286-27-00.